5C). addition, the BAL itself from MSC-treated mice experienced a greater antimicrobial activity in comparison with the BAL of phosphate buffered saline (PBS)-treated mice. Human being bone marrow-derived MSCs possess direct antimicrobial activity, which is definitely mediated in part from the secretion of human being cathelicidin hCAP-18/LL-37. Keywords: Acute lung injury/acute respiratory distress syndrome, Antimicrobial peptides/proteins, pneumonia, LL-37, Mesenchymal stem cells Intro The innate immune system provides the 1st line of defense against microbial infections. Among the key effector molecules responsible for bacterial killing are antimicrobial proteins and polypeptides, which comprise a varied group, including lysozyme, lactoferrin, secretory leucoprotease inhibitor, and defensins, all of which are able to destroy microorganisms [1]. The cathelicidin family is one of the main antimicrobial peptide family members in mammals [2]. Peptides belonging to the cathelicidin family are either constitutively produced or induced on activation [3, 4]. Cathelicidins as well as the majority of known antimicrobial peptides exert their microbicidal activity through the disruption of the integrity of bacterial membranes [5]. In humans, the cathelicidin family of antimicrobial peptides is definitely represented by a 4 kDa peptide, hCAP-18/LL-37, that is primarily produced by phagocytic CP-690550 (Tofacitinib citrate) leukocytes and epithelial cells, but it is also indicated in the bone marrow [6] and by mesenchymal stem cells (MSCs) [7]. LL-37 has a wide range of biological activities including direct killing of microorganisms, chemotaxis and chemokine induction, and rules of inflammatory reactions, as well as angiogenic, antiapoptotic, aids in horizontal DNA intracellular transfer, and wound healing effects [8, 9]. MSCs are multipotent adult stem cells found in the bone marrow and additional anatomic niches, which have the capacity to differentiate into multiple cell types such as osteoblasts, adipocytes, and chondroblasts under in vitro conditions [10, 11]. Bone marrow (BM)-derived MSCs reside near the sinusoids and function as support cells for hematopoietic stem cells, maybe providing some safety against microbial invasion. Although it is definitely well established that MSCs have toll-like receptor (TLR) receptors [12C15] and are involved in inflammatory reactions [16], little is known about their part in the innate immune system. Acute lung injury (ALI) is definitely a major cause of acute respiratory failure in critically ill individuals. Bacterial pneumonia is the most common cause of ALI [17]. Recent studies have shown that BM-derived MSCs reduce lung injury in experimental models of lipopolysaccharide (LPS)-induced ALI in mouse [18, 19] and in an ex lover vivo-perfused human being lung [20]. In addition, additional in vitro and in vivo studies have provided evidence for the beneficial effects of MSCs in the treatment of LPS- or bacteria-induced sepsis. In two mouse models of sepsis following cecal ligation and puncture (CLP), i.v. MSCs reduced total bacterial counts in the blood and peritoneal fluid [21, 22]. These survival benefits were explained in part from the immunomodulatory properties of MSCs, CP-690550 (Tofacitinib citrate) but the actual mechanism of enhanced bacterial clearance was not clearly recognized. Although a recent publication by Mei et al. [23] showed the improvement in bacterial clearance in MSC-treated septic mice following CLP could be in part explained by enhanced phagocytic activity of sponsor immune cells, it is not known yet whether human being BM-derived MSCs possess direct antimicrobial activity. Therefore, the primary hypothesis for these studies was that human being MSCs might communicate direct antimicrobial activity through the secretion of antimicrobial peptides. We examined the effect of human being CP-690550 (Tofacitinib citrate) MSCs on bacterial growth in vitro. Manifestation of different antimicrobial peptides was investigated using reverse transcription polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry. Following activation with live pneumonia model in mice. Treatment with human being MSCs, given 4 hours later on, resulted in a significant reduction of Rabbit polyclonal to AIM2 colony-forming unit (CFU) in the lung homogenates (LHs) and the bronchoalveolar lavage (BAL) fluids. The effect was blocked having a neutralizing antibody to LL-37 demonstrating that human being MSCs possessed antimicrobial activity, which is definitely explained in part from the secretion of LL-37. Materials and Methods Chemicals and Reagents LPS (O55:B5) was purchased from Sigma-Aldrich (St. Louis, MO). Mouse monoclonal antibody to human being LL37/CAP18 clone 3D11 and mouse isotype IgG1 antibody were purchased from Hycult Biotechnology (Netherlands), goat Alexa-Fluor 488-labeled anti-mouse-IgG from Invitrogen, synthetic human being LL-37 from AnaSpec (CA) and fetal bovine serum (FBS) from HyClone Laboratories Inc. (Utah). Animals C57BL/6 male mice (8- to 10-weeks aged; Jackson Laboratory) were used in all experiments. Animals were managed in the animal facility in the University or college of California, San Francisco (UCSF). All experimental protocols were authorized by the Institutional Animal Care and Use Committee at UCSF..